TNR
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Torian Resources Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Torian Resources Limited
📈 Performance
Price History
+800.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.04
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in TNR
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
27 weeks
💵 Average investment amount
$1,568
⏰ Last time a customer invested in TNR
1020 days
TNR investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in TNR also invest in...
Asra Minerals Ltd. engages in the development and exploration of mineral properties. The company is headquartered in Perth, Western Australia. The firm is focused on targeting a growing gold, lithium and rare earth element (REE) portfolio in the premier Goldfields region of Western Australia. The Company’s flagship Mt Stirling Project is located 240 kilometers (km) north of Kalgoorlie and hosts 10 gold prospects, and a gold JORC Mineral Resource. The project also has a potential for REE and critical minerals including scandium. Its Kookynie West Project is situated less than 50km south, which is an underexplored site showing gold, lithium and REE potential. The company also has two lithium-focused exploration projects in the southern Yilgarn area of Western Australia at Lake Johnston and Lake Cowan, located in highly prospective ground between operating lithium mines at Earl Grey and Bald Hill. Its footprint in the Eastern Goldfields region stands at approximately 1,134 square kilometers (km2).
🙌 Performance (5Yr p.a)
-14.05%
📊 Share price
$0.00 AUD
⛏️ MINING
CGS
Cogstate Ltd. is a global cognitive science company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-02-13. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
🙌 Performance (5Yr p.a)
30.00%
📊 Share price
$0.97 AUD
📈 HIGH PRICE GROWTH
🩺 HEALTH CARE
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
🙌 Performance (5Yr p.a)
-5.42%
📊 Share price
$0.03 AUD
🧬 BIOTECHNOLOGY
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The firm is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. The company holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.
🙌 Performance (5Yr p.a)
-16.36%
📊 Share price
$0.00 AUD
📦 LOGISTICS